Mohamed B. Elmongy, MD, MPH, DSc - LSUHSC School of Medicine

Administration	Basic Sciences	Clinical Sciences	Centers of Excellence
Admissions Alumni Affairs Community and Minority Health Education Computer Support Continuing Education Dean's Office Faculty & Institutional Affairs Fiscal Affairs Libraries Medical Education Research Student Affairs	Biochemistry & Molecular Biology Cell Biology & Anatomy Genetics Microbiology, Immunology & Parasitology Pharmacology Physiology	Anesthesiology Dermatology Family Medicine Internal Medicine Emergency Medicine Gastroenterology Physical Medicine & Rehabilitation Neurology Neurosurgery OB/GYN Ophthalmology Orthopaedics Otorhinolaryngology Pathology Pediatrics Psychiatry Radiology Surgery Urology	Alcohol and Drug Abuse Center Cardiovascular Center Center on Healthy Aging Center for Molecular and Human Genetics Epilepsy Center Eye Center Ernest N. Morial Asthma, Allergy, and Respiratory Disease Center Gene Therapy Program Low Vision Center Neurosciences Center The Research Institute For Children Stanley S. Scott Cancer Center

Faculty

Residency

Fellowship

Research

Links

Sections

Curriculum

New Orleans

Department Title

	Mohamed B. Elmongy, MD, MPH, DSc Professor of Clinical Medicine Section of Hematology/Oncology 2020 Gravier St., E7-20 New Orleans, LA 70112 Phone 504-568-8005 Fax 504-568-2127 melmon@lsuhsc.edu
Degrees	MD - 1975 Cairo University, Cairo, Egypt MPH - 1981 Tulane University, New Orleans, Louisiana DSc - 1985 Tulane University, New Orleans, Louisiana
Bio	Dr. Elmongy earned his medical degree from Cairo University, Department of Medicine, and he completed his residency in Internal Medicine and his fellowship in Hematology/Medical Oncology at Tulane’s School of Medicine. He completed an additional fellowship in the Leukemia and Bone Marrow Transplantation Program at Vancouver General Hospital and the British Columbia Cancer Agency, Vancouver, Canada. In 1992, Dr. Elmongy became Director of the Leukemia/Bone Marrow Transplant Program and Assistant Professor at Harrington Cancer Center, Texas Tech University Health Science Center. He also served as Chief of Hematology at Texas Tech affiliated VA Medical Center. He returned to New Orleans in 1994 to become Director of the Leukemia, Blood, and Marrow Transplantation Program at Memorial Medical Center, where he developed the first accredited program and one of the most successful programs in the region -- a program recognized for its reputation, patient outcome, volume, and revenues. In 2002, he started the cancer program at Kenner Regional Medical Center and served as its director for two years. Following this, he spent three years working on clinical & Translational research for oncology drug development including molecularly targeted compounds. Dr. Elmongy was selected as one of America’s Top Rated Specialists in Oncology and Stem Cell Transplantation by the Center for Study of Service in 1999. He was selected by New Orleans Magazine as one of the top oncologists in New Orleans in 2000, 2001, and 2003. He received the Spirit Award from the American Cancer Society in 2003. In 2007, he joined the faculty of the University of Florida’s Sands Cancer Center, where he was Associate Professor of Medicine in Hematology/Oncology and Director of the Solid Tumor Clinical Research Program. Dr. Elmongy joined the faculty of LSU School of Medicine in 2008. He ihas been board certified in Internal Medicine since 1988 and in Medical Oncology since 1989.
Clinical Interests	Hematopoietic Stem Cell Transplantation Hematological Malignancies: • Acute Leukemia’s • Chronic Myeloid Leukemia & Chronic Lymphocytic Leukemia • Non Hodgkin’s Lymphomas & Hodgkin’s Disease • Myelodysplastic syndrome • Multiple Myeloma Breast Cancer GU Malignancies
Research Interests	Clinical Trials of : • Developmental Therapeutics of molecularly targeted compounds • Biologic and Immunologic Therapy • Cancer Vaccine Development
Selected Publications	Wingard JR and Elmongy MB. Strategies for Minimizing Neutropenic fever’s Complications: Prophylactic myeloid growth factors or antibiotics. Accepted for publications: Critical Reviews in Oncology Hematology, 02/2009. Elmongy MB, Stolier A, Linares L, Seiler M, Concurrent use of taxol and radiation therapy for the adjuvant treatment of cancer of the breast. 22nd Annual San Antonio Breast Cancer Symposium December 8-11, 1999. Reece DE, Elmongy MB, Barnett MJ, Klingemann H-G, Shepherd JD & Phillips GL. Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. Cancer Invest 1993; 11(5): 509-16. Nevill TJ, Elmongy MB, Shepherd JD, Reece DE, Klingemann H-G, Barnett MJ, Nantel SH, Phillips GL. The influence of donor parity on the incidence of graft-versus-host disease (GVHD), relapse and event-free survival (EFS) in patients (PTS) undergoing allogeneic bone marrow transplantation (BMT). Blood 78 (Suppl 1): 233a, 1991. Elmongy MB, Reece DE, Barnett MJ, Shepherd JD, Nantel SH, Klingemann H-G, Bow E, Shore T, Phillips GL. Comparative study of bone marrow transplantation (BMT) vs. high dose cytarabine (HIDAC)-based chemotherapy (CTX) regimens in first remission acute myeloid leukemia (AML). Blood 78 (Suppl 1): 1991 Elmongy, MB, Nevill TJ, Klingemann H-G, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Phillips GL. Cyclosporine (CSA) and methotrexate (MTX) vs. CSA and methylprednisolone (MP) for graft-vs. -Host disease (GVHD) prophylaxis. Blood 78 (Suppl 1): 223a, 1991. Elmongy MB, Shepherd JD, Reece DE, Barnett MJ, Klingemann H-G, Phillips GL. Second bone marrow transplantation (BMT) for patients (PTS) with hematologic malignancies who relapse following first BMT. Clin Inves Med 14 (Suppl A): 59, 1991. Elmongy MB, Nevill T, Barnett M, Reece D, Shepherd J, Klingemann H-G, Phillips G. Etoposide (VP-16), cyclophosphamide (CY) and total body irradiation (TBI) conditioning and donor bone marrow transplantation (BMT) for lymphoid malignancies. Clin Invest Med 14 (Suppl A): 60, 1991. Elmongy MB, Barnett MJ, Bow E, Klingemann H-G, Reece DE, Shepherd JD, Shore T, Phillips GL. Allogeneic bone marrow transplantation (BMT) vs. high dose cytarabine (HIDAC) based chemotherapy (CTX) regimens in first remission acute myeloid leukemia (AML) Proc Am Soc Clin Oncol 10:227, 1991. Elmongy MB, Barnett MJ, Klingemann H-G, Lansdorp P, Reece DE, Shepherd JD, Phillips GL. A phase I/II study of the treatment of acute myelogenous leukemia (AML) using busulfan (BU) and carboplatin (CBCDA) conditioning and 4-hydroperoxycyclophosphamide (4-HC) purged autologous bone marrow transplantation (BMT). Clin Invest Med 13 (Suppl B): 45, 1990.